Literature DB >> 8359087

Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin.

S N Murthy1, H S Cooper, H Shim, R S Shah, S A Ibrahim, D J Sedergran.   

Abstract

The use of oral and intravenous cyclosporin represents a significant advance in the therapy of refractory inflammatory bowel diseases (IBD). However, oral administration of cyclosporin is fraught with improper delivery of cyclosporin to the colon for its topical action. Because of unpredictable metabolism by cytochrome P-450 IIIA, the targeted blood level for systemic effect is not reached at low doses. Furthermore, the doses that have been used for therapy of IBD have been shown to induce several adverse side effects. Thus, an alternate method of delivering cyclosporin to the colon is desirable. In this study, the effect of intracolonically administered cyclosporin was tested for its efficacy to heal mucosal erosions in dextran sulfate sodium (DSS)-induced colitis in mice. Both acute and chronic colitis was induced by feeding female Swiss-Webster mice with 5% DSS (30,000-40,000 mol wt) for five or seven days, respectively. Therapy was advocated prophylactically, prophylaxis plus therapy and therapeutically during the acute and chronic phase of the disease and therapeutically during the chronic phase of the disease. Intracolonic cyclosporin given prophylactically showed adverse effects by increasing the damage to the colonic mucosa. However, intracolonic cyclosporin given therapeutically in 2.5, 5, and 10 mg/kg after the induction of colitis resulted in dramatic responses in terms of reducing the disease activity and histologic scores, corroborated by complete histological resolution compared to oral cyclosporin given at identical doses. Intracolonic cyclosporin (5 mg/kg) was also very effective in reducing the chronic inflammation. The results of this study highlight the application of this animal model for therapeutic research. Furthermore, cyclosporin administered as an enema provides a new stratagem for the therapy of IBD because of its rapid onset of action at very low doses without the risk inherent in oral or systemic administration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359087     DOI: 10.1007/bf01303184

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Treatment of refractory ulcerative colitis with cyclosporin enemas.

Authors:  J Brynskov; L Freund; O O Thomsen; C B Andersen; S N Rasmussen; V Binder
Journal:  Lancet       Date:  1989-04-01       Impact factor: 79.321

2.  Hapten-induced model of chronic inflammation and ulceration in the rat colon.

Authors:  G P Morris; P L Beck; M S Herridge; W T Depew; M R Szewczuk; J L Wallace
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

3.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.

Authors:  I Okayasu; S Hatakeyama; M Yamada; T Ohkusa; Y Inagaki; R Nakaya
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

4.  Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat.

Authors:  P Kubes; J Hunter; D N Granger
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

5.  Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs.

Authors:  A W Thomson; D K Moon; Y Inoue; C L Geczy; D S Nelson
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

6.  Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.

Authors:  S Meyers; D B Sachar; D H Present; H D Janowitz
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

Review 7.  New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.

Authors:  M G Robinson
Journal:  Gastroenterol Clin North Am       Date:  1989-03       Impact factor: 3.806

Review 8.  6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.

Authors:  D H Present
Journal:  Gastroenterol Clin North Am       Date:  1989-03       Impact factor: 3.806

9.  Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.

Authors:  L R Fitzpatrick; J S Bostwick; M Renzetti; R G Pendleton; D L Decktor
Journal:  Agents Actions       Date:  1990-06

10.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  180 in total

1.  Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide.

Authors:  Xue Hua Pang; Tian Ke Li; Qin Xie; Fu Qian He; De Jun Cui; You Qin Chen; Xiao Li Huang; Hua Tian Gan
Journal:  Int J Colorectal Dis       Date:  2010-06-05       Impact factor: 2.571

2.  Emu oil increases colonic crypt depth in a rat model of ulcerative colitis.

Authors:  Suzanne M Abimosleh; Ruth J Lindsay; Ross N Butler; Adrian G Cummins; Gordon S Howarth
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

3.  Induction of colitis in mice deficient of Peyer's patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches.

Authors:  Thomas W Spahn; Hermann Herbst; Paul D Rennert; Norbert Lügering; Christian Maaser; Mathias Kraft; Adriano Fontana; Howard L Weiner; Wolfram Domschke; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Alleviation effects of Bifidobacterium breve on DSS-induced colitis depends on intestinal tract barrier maintenance and gut microbiota modulation.

Authors:  Yang Chen; Yan Jin; Catherine Stanton; R Paul Ross; Jianxin Zhao; Hao Zhang; Bo Yang; Wei Chen
Journal:  Eur J Nutr       Date:  2020-04-29       Impact factor: 5.614

5.  Atm-deficient mice exhibit increased sensitivity to dextran sulfate sodium-induced colitis characterized by elevated DNA damage and persistent immune activation.

Authors:  Aya M Westbrook; Robert H Schiestl
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

6.  Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice.

Authors:  Leo R Fitzpatrick; Vineeta Khare; Jeffrey S Small; Walter A Koltun
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

7.  IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Yoshihide Asano; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

8.  Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid.

Authors:  Mansour Mohamadzadeh; Erika A Pfeiler; Jeffrey B Brown; Mojgan Zadeh; Matthew Gramarossa; Elizabeth Managlia; Praveen Bere; Bara Sarraj; Mohammad W Khan; Krishna Chaitanya Pakanati; M Javeed Ansari; Sarah O'Flaherty; Terrence Barrett; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

9.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.

Authors:  B Siegmund; H A Lehr; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

10.  Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice.

Authors:  A Minocha; C Thomas; R Omar
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.